Data Confirm Benefit of Cobimetinib and Vemurafenib in Melanoma

Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study published in the journal The Lancet Oncology have shown.1

Previously reported findings from the phase 3 coBRIM study demonstrated that cobimetinib plus vemurafenib improves progression-free survival compared with placebo and vemurafenib in treatment-naïve patients with BRAF V600-mutant advanced melanoma. After longer follow-up, the investigators of the coBRIM study now report overall survival and additional safety results.

For the multicenter, double-blind study, investigators enrolled 495 adult patients with histologically confirmed BRAF V600 mutation-positive unresectable stage IIIC or IV melanoma. Participants were randomly assigned 1:1 to receive cobimetinib 60 mg orally once daily for 21 days followed by a 7-day rest period in each 28-day cycle or placebo, in combination with vemurafenib 960 mg orally twice daily.

At a median follow-up of 14.2 months, results showed that the updated investigator-assessed median progression-free survival was 12.3 months (95% CI, 9.5-13.4) for cobimetinib and vemurafenib compared with 7.2 months (95% CI, 5.6-7.5) for placebo and vemurafenib (hazard ratio [HR], 0.58; 95% CI, 0.46-0.72; P <.0001).

Researchers also found that median overall survival was 22.3 months (95% CI, 20.3-not estimable) for cobimetinib and vemurafenib vs 17.4 months (95% CI, 15.0-19.8) for placebo plus vemurafenib (HR, 0.70; 95% CI, 0.55-0.90; P =.005).

In terms of safety, no new safety signals were observed with longer follow-up. The most common grade 3 to 4 adverse events that occurred at a higher frequency in the cobimetinib group vs the placebo group were γ-glutamyl transferase elevation, blood creatine phosphokinase elevation, and alanine transaminase elevation.

Of note, serious adverse events were reported in 37% of cobimetinib-treated patients compared with 28% of those in the placebo arm.

Reference

1. Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 Jul 29. doi: 10.1016/S1470-2045(16)30122-X. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs